The invention provides methods for assessing increased probability of having Alzheimer's disease in a subject under assessment including a step of obtaining a measurement of Abeta40 aggregates in a biological sample from the subject, where the biological sample does not include brain tissue, a fraction of brain tissue, or brain homogenate. In some embodiments, the invention relates to methods of assessing increased probability of early stage Alzheimer's disease. The invention further provides methods of assessing increased probability of not having Alzheimer's disease, methods of monitoring disease progression in a subject with Alzheimer's disease, and methods of assigning disease stage for a subject with Alzheimer's disease, and methods of assessing increased probability of MCI progressing to Alzheimer's disease.
AMYLOID BETA AGGREGATES IN CEREBRO SPINAL FLUID AS BIOMARKERS FOR ALZHEIMER'S DISEASE